NASDAQ · Biotechnology · USD
Actuate Therapeutics, Inc. Common stock (ACTU) Stock Analysis
Actuate Therapeutics, Inc. Common stock (ACTU) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ACTU Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.60
- Previous Close
- $0.62
- Day's Range
- 0.56–0.64
- 52-Week Range
- 0.41–7.90
- Volume
- 220.37K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.20
Valuation
- Market Cap
- $13.50M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.87
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$22.23M
- Shares Outstanding
- 24.01M
- 1-Year Return
- −92.34%
Dividend and dates
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 351.19K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ACTU closed at $0.56, −92.34% over 1 year.
Actuate Therapeutics, Inc. Common stock (ACTU) has a market capitalization of $13.50M.
In fiscal 2025, ACTU reported revenue of $0.00.
ACTU Stock Return by Calendar Year
Actuate Therapeutics, Inc. Common stock (ACTU) return since Aug 2024: what $10,000 became
- 1 year
- $10,000 $766
- −92.34%
- Since Aug 2024
- $10,000 $653
- −93.47%
If you had invested $10,000 in Actuate Therapeutics, Inc. Common stock (ACTU) at the close on August 13, 2024, the earliest close on record here, it would have been worth $653 at the close on October 21, 2026: −93.47% in total, −71.28% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −90.81% |
| 2025 | −23.12% |
| 2024 (partial year) | −7.55% |
As of October 21, 2026.
ACTU Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$22.23M | — |
| 2024 | $0.00 | −$27.29M | — |
| 2023 | $0.00 | −$24.74M | — |
| 2022 | $0.00 | −$20.16M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$22.50M | −$22.23M | — |
| 2024 | $0.00 | — | −$25.16M | −$27.29M | — |
| 2023 | $0.00 | — | −$24.97M | −$24.74M | — |
| 2022 | $0.00 | — | −$20.21M | −$20.16M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Actuate Therapeutics To Sell 50,000,000 Shares At Assumed Price Of $0.819 Per Share
BenzingaActuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
YahooActuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
YahooHC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target
BenzingaRodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B